Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients With Advanced Breast or Prostate Carcinomas With Metastases to Bone and Receiving Ongoing Therapy With Denosumab or Zoledronic Acid

NCT02274623 is registered in ClinicalTrials.gov with OPKO Health, Inc. as lead sponsor.

NCT NCT02274623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02274623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients With Advanced Breast or Prostate Carcinomas With Metastases to Bone and Receiving Ongoing Therapy With Denosumab or Zoledronic Acid
Lead sponsor
OPKO Health, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2014
Completion date
March 17, 2017
Enrollment
33 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bone neoplasms, breast cancer, hyperparathyroidism, secondary, hypocalcemia, prostate cancer